Core Viewpoint - China National Pharmaceutical Group Corporation (Sinopharm Group) announced the transfer of 25% equity in Sinopharm Traditional Chinese Medicine Co., Ltd. to Shanghai Tianyue Tenghua Trading Service Co., Ltd. This transfer will be completed by September 30, 2025, and will result in Sinopharm Traditional Chinese Medicine no longer holding any equity in Sinopharm Medicinal Materials Co., Ltd. [1][2] Group 1 - After the equity transfer, Sinopharm Traditional Chinese Medicine will not hold any shares in Sinopharm Medicinal Materials, and there will be no equity or control relationship between Sinopharm Group, Sinopharm Traditional Chinese Medicine, and Sinopharm Medicinal Materials [2] - Sinopharm Group has never authorized Sinopharm Medicinal Materials or its subsidiaries to use its trademarks or engage in activities under its name, and it does not take responsibility for any actions taken by Sinopharm Medicinal Materials [2][3] - Sinopharm Medicinal Materials has been using Sinopharm Group's trademarks and names without authorization, which constitutes serious infringement, and legal actions have been initiated to hold them accountable [3] Group 2 - Sinopharm Group is a central enterprise directly managed by the State-owned Assets Supervision and Administration Commission, focusing on life and health, and is a leader in the global industry with a comprehensive strength in various sectors including R&D, manufacturing, logistics, retail, and financial investment [5] - The group comprises over 1,600 member enterprises, including listed companies such as Sinopharm Holdings, Sinopharm Shares, and Tian Tan Biology [5]